KTKazuki Takahashi

Kazuki Takahashi

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Kazuki Takahashi has a total of 84 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Data from DS-3939a: A TA-MUC1–Directed Antibody–Drug Conjugate with Broad Antitumor Activity

    by Kohei Takano, Mayuko Yukiura, Kazuki Takahashi, Michiko Kitamura, Hiroko Okuno, Yoshinobu Shiose, Kokichi Honda, Kazunori Oyama, Makiko Yamada, Wataru Obuchi, et al.

    Tumor-associated mucin-1 (TA-MUC1) is a glycoform of the MUC1 protein that is aberrantly glycosylated and is primarily observed in cancer cells. TA-MUC1 is highly expressed in various human epithelial cancers, making it an attractive target for cancer therapies. In this study, we describe the development of DS-3939a, a novel TA-MUC1–targeting antibody–drug conjugate that utilizes the potent DNA topoisomerase I inhibitor DXd, and evaluation of its pharmacologic activity in preclinical in vitro and in vivo models. IHC of clinical tumor tissue microarrays of various cancer types exhibited positive staining for TA-MUC1 in a number of samples, with a particularly high positive rate in bladder, lung, and breast cancers. In vitro profiling of DS-3939a confirmed that it could specifically bind to TA-MUC1 and inhibit the growth of TA-MUC1–positive cancer cells by inducing DNA damage and apoptosis. DS-3939a also exhibited significant antitumor effects in multiple TA-MUC1–positive cell line–derived and patient-derived xenograft models. Moreover, DS-3939a elicited strong tumor regression in several xenograft models even following treatment with other cytotoxic antibody–drug conjugates, likely through its efficient payload delivery. Overall, these data provide evidence for the potential utility of DS-3939a for the treatment of TA-MUC1–expressing tumors and support the rationale for the ongoing phase I/II clinical study (NCT05875168).

  • Open Access

    Figure S4 from DS-3939a: A TA-MUC1–Directed Antibody–Drug Conjugate with Broad Antitumor Activity

    by Kohei Takano, Mayuko Yukiura, Kazuki Takahashi, Michiko Kitamura, Hiroko Okuno, Yoshinobu Shiose, Kokichi Honda, Kazunori Oyama, Makiko Yamada, Wataru Obuchi, et al.

    Binding activity of assay control antibodies against MUC1 peptides was evaluated by ELISA.

  • Open Access

    Figure S3 from DS-3939a: A TA-MUC1–Directed Antibody–Drug Conjugate with Broad Antitumor Activity

    by Kohei Takano, Mayuko Yukiura, Kazuki Takahashi, Michiko Kitamura, Hiroko Okuno, Yoshinobu Shiose, Kokichi Honda, Kazunori Oyama, Makiko Yamada, Wataru Obuchi, et al.

    Photomicrograph of human normal tissues showing positive for TA-MUC1.

  • Open Access

    Figure S6 from DS-3939a: A TA-MUC1–Directed Antibody–Drug Conjugate with Broad Antitumor Activity

    by Kohei Takano, Mayuko Yukiura, Kazuki Takahashi, Michiko Kitamura, Hiroko Okuno, Yoshinobu Shiose, Kokichi Honda, Kazunori Oyama, Makiko Yamada, Wataru Obuchi, et al.

    Expression level and internalization of each ADC target.

  • Open Access

    Figure S1 from DS-3939a: A TA-MUC1–Directed Antibody–Drug Conjugate with Broad Antitumor Activity

    by Kohei Takano, Mayuko Yukiura, Kazuki Takahashi, Michiko Kitamura, Hiroko Okuno, Yoshinobu Shiose, Kokichi Honda, Kazunori Oyama, Makiko Yamada, Wataru Obuchi, et al.

    Amino acid sequences of anti-TA-MUC1 antibody.

  • Open Access

    Figure S2 from DS-3939a: A TA-MUC1–Directed Antibody–Drug Conjugate with Broad Antitumor Activity

    by Kohei Takano, Mayuko Yukiura, Kazuki Takahashi, Michiko Kitamura, Hiroko Okuno, Yoshinobu Shiose, Kokichi Honda, Kazunori Oyama, Makiko Yamada, Wataru Obuchi, et al.

    Representative images of human tumor tissues analyzed by IHC staining for TA-MUC1 with moderate and strong staining intensities in select cancer types.

  • Open Access

    Figure S5 from DS-3939a: A TA-MUC1–Directed Antibody–Drug Conjugate with Broad Antitumor Activity

    by Kohei Takano, Mayuko Yukiura, Kazuki Takahashi, Michiko Kitamura, Hiroko Okuno, Yoshinobu Shiose, Kokichi Honda, Kazunori Oyama, Makiko Yamada, Wataru Obuchi, et al.

    Correlation analysis of the efficacy of DS-3939a and TA-MUC1 expression in evaluated PDX models.

  • Open Access

    Figure S5 from Targeting KRAS Inhibitor–Resistant Pancreatic Cancer with an MUC1-C Antibody–Drug Conjugate

    by Hiroki Ozawa, Kazuki Takahashi, Tomoki Motegi, Justine Jacobi, Atrayee Bhattarchya, Keisuke Shigeta, Shinkichi Takamori, Mai Onishi, Zhou Luan, Kazumasa Fukuda, et al.

    Supplemental Figure S5. M1C regulates IFN type I/II pathway genes. A-D. Analysis of genes significantly (i) upregulated in AsPC-1/MR vs AsPC-1 cells, and (ii) downregulated in AsPC-1/MR cells with M1C silencing using the HALLMARK INTERFERON ALPHA (A,B) and GAMMA (C,D) gene signatures. Violin plots illustrate the distribution of mean Z-scores for each gene signature. Group differences were determined by multivariate testing using meta-scores. E and F. Lysates from AsPC-1 (E) and PANC-1 (F) cells expressing the indicated vectors and treated with vehicle or DOX for 7 days, followed by vehicle or 50 nM (E) and 1 µM (F) MRTX-1133 for 2 days were immunoblotted with antibodies against the indicated proteins. G. AsPC-1/MR/CshRNA and AsPC-1/MR/MUC1shRNA#2 cells treated with 1 μM MRTX1133 for 6 days were analyzed for colony formation. Shown are representative photomicrographs of stained colonies. H. PANC-1/MR/CshRNA and PANC-1/MR/MUC1shRNA#2 cells treated with 1 μM MRTX1133 for 6 days were analyzed for colony formation. Shown are representative photomicrographs of stained colonies. I. Lysates from AsPC-1/MR/CshRNA, AsPC-1/MR/STAT1shRNA#1 and AsPC-1/MR/STAT1shRNA#2 were immunoblotted with antibodies against the indicated proteins. J. Lysates from PANC-1/MR/CshRNA, PANC-1/MR/STAT1shRNA#1 and PANC-1/MR/STAT1shRNA#2 were immunoblotted with antibodies against the indicated proteins. K. AsPC-1/MR/CshRNA, AsPC-1/MR/STAT1shRNA#1, AsPC-1/MR/STAT1shRNA#2 cells treated with 1 μM MRTX1133 for 6 days were analyzed for colony formation. Shown are representative photomicrographs of stained colonies. L. PANC-1/MR/CshRNA, PANC-1/MR/STAT1shRNA#1, PANC-1/MR/STAT1shRNA#2 cells treated with 1 μM MRTX1133 for 6 days were analyzed for colony formation. Shown are representative photomicrographs of stained colonies. M. AsPC-1/MR/CshRNA, AsPC-1/MR/STAT1shRNA#1 and AsPC-1/MR/STAT1shRNA#2 cells treated with the indicated concentrations of MRTX1133 for 3 days were analyzed for cell viability by Alamar Blue staining. The results (mean±SD of four determinations) are expressed as relative cell number compared to that for CshRNA cells (assigned a value of 1). N. PANC-1/MR/CshRNA, PANC-1/MR/STAT1shRNA#1 and PANC-1/MR/STAT1shRNA#2 cells treated with the indicated concentrations of MRTX1133 for 3 days were analyzed for cell viability by Alamar Blue staining. The results (mean±SD of four determinations) are expressed as relative cell number compared to that for CshRNA cells (assigned a value of 1).

  • Open Access

    Figure S8 from Targeting KRAS Inhibitor–Resistant Pancreatic Cancer with an MUC1-C Antibody–Drug Conjugate

    by Hiroki Ozawa, Kazuki Takahashi, Tomoki Motegi, Justine Jacobi, Atrayee Bhattarchya, Keisuke Shigeta, Shinkichi Takamori, Mai Onishi, Zhou Luan, Kazumasa Fukuda, et al.

    Supplemental Figure S8. Analysis of patient-derived organoids for M1C expression and sensitivity to the M1C ADC. A and B. Lysates from PF108 (A) and PF405 (B) cells treated with 1 μM MRTX1133 for 2 days were immunoblotted with antibodies against the indicated proteins. C. Patient-derived organoids treated with the indicated M1C ADC concentrations for 6 days were analyzed for cell viability by CellTiter-Glo 3D Cell Viability Assay. The results (mean±SD of five determinations) are expressed as relative cell number (% control) compared to that for untreated cells. Indicated are the M1C ADC IC50 values. D. Patient-derived organoids were treated with the indicated concentrations of M1C ADC and MRTX1133 for 6 days. Cell viability was assessed using the CellTiter-Glo 3D Cell Viability Assay (mean of five determinations). Indicated are the combination indices determined using Bliss scores.

  • Open Access

    Figure S7 from Targeting KRAS Inhibitor–Resistant Pancreatic Cancer with an MUC1-C Antibody–Drug Conjugate

    by Hiroki Ozawa, Kazuki Takahashi, Tomoki Motegi, Justine Jacobi, Atrayee Bhattarchya, Keisuke Shigeta, Shinkichi Takamori, Mai Onishi, Zhou Luan, Kazumasa Fukuda, et al.

    Supplemental Figure S7. ST-00013312-T cells are sensitive to treatment with the M1C ADC. A. AsPC-1/MR cells cultured in the absence of MRTX1133 for 30 days and then with the indicated concentrations of MRTX1133 for 3 days were analyzed for cell viability by Alamar Blue staining. The results (mean±SD of six determinations) are expressed as relative cell number (% control) compared to that for untreated cells. Indicated is the MRTX1133 IC50 value. B. Mean body weight changes of the AsPC-1/MR tumor bearing mice treated with vehicle or M1C ADC. The results are expressed as the mean ratio of relative body weight ± SEM. C. Mean body weight changes of the PANC-1/MR tumor bearing mice treated with vehicle or M1C ADC. The results are expressed as the mean ratio of relative body weight ± SEM. D. ST-00013312-T cells treated with the indicated concentrations of MRTX1133 for 3 days were analyzed for cell viability by Alamar Blue staining. The results (mean±SD of six determinations) are expressed as relative cell number (% control) compared to that for untreated cells. Indicated is the MRTX1133 IC50 value. E. ST-00013312-T cells treated with vehicle, 5 µM GO-203 and 1 µM MRTX1133 for 6 days were analyzed for colony formation. Shown are representative photomicrographs of stained colonies. F. ST-00013312-T cells treated with the indicated concentrations of M1C ADC for 6 days were analyzed for cell viability by Alamar Blue staining. The results (mean±SD of four determinations) are expressed as relative cell number (% control) compared to that for untreated cells. Indicated is the M1C ADC IC50 value. G. ST-00013312-T cells treated with vehicle, 50 nM M1C ADC and 1 µM MRTX1133 for 6 days were analyzed for colony formation. Shown are representative photomicrographs of stained colonies. H. Mean body weight changes of ST-00013312-T tumor bearing mice treated with vehicle or M1C ADC. The results are expressed as the mean ratio of relative body weight ± SEM.